Anna D. Staniszewska
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, Phytochemicals and Medicinal Plants, Toxin Mechanisms and Immunotoxins, Ovarian cancer diagnosis and treatment
Most-Cited Works
- → Stat3 controls lysosomal-mediated cell death in vivo(2011)307 cited
- → Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer(2018)189 cited
- → Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS(2017)177 cited
- → Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper(2022)161 cited
- → Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs(2021)131 cited
- → Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions(2018)110 cited
- → Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery(2019)99 cited
- → PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity(2018)85 cited
- → VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells(2014)59 cited
- → Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305(2022)56 cited